Logo image
Semaglutide reduced a composite of CV events at 2 years in patients with type 2 diabetes and high CV risk
Journal article   Peer reviewed

Semaglutide reduced a composite of CV events at 2 years in patients with type 2 diabetes and high CV risk

Anthony A Donato
Annals of internal medicine, v 166(2), JC8
17 Jan 2017
PMID: 28114464

Abstract

Cardiovascular Diseases Diabetes Mellitus, Type 2 Diabetic Angiopathies Glucagon-Like Peptides Humans Risk Risk Factors

Metrics

1 Record Views

Details

Logo image